Therapeutic vaccination: Hope for untreatable tuberculosis?

Journal of Infectious Diseases

Volumn 207, Issue 8, 2013, Pages 1193-1194

  McMurray, David N ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GLUCOPYRANOSIL LIPID A; ISONIAZID; LIPID A; MW VACCINE; RIFAMPICIN; RUTI VACCINE; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG SENSITIVE TUBERCULOSIS; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION PREVENTION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM VACCAE; NONHUMAN; NOTE; PRIORITY JOURNAL; TUBERCULOSIS;

ANIMALS; ANTIGENS, BACTERIAL; ANTITUBERCULAR AGENTS; FEMALE; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY;

EID: 84875577372     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis429     Document Type: Note

References (14)

1. Dye C, Williams BG. The population dynamics and control of tuberculosis. Science 2010; 328:856-61.
2. Vadwai V, Boehme C, Nabeta P, et al. Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis? J Clin Micro 2011; 49:2540-5.
3. Koul A, Arnoult E, Lounis N, et al. The challenge of new drug discovery for tuberculosis. Nature 2011; 469:483-90.
4. Griffiths G, Nystrom B, Sable SB, Khuller GK. Nanobead-based interventions for the treatment and prevention of tuberculosis. Nat Rev Microbiol 2010; 8:827-34.
5. Graves AJ, Hokey DA. Tuberculosis vaccines: review of current develop trends and future challenges. J Bioterr Biodef 2011; S1:009.
6. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 2009; 7:81-7.
7. Coler RN, Bertholet S, Pine SO, et al. Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct of antibiotic therapy. J Infect Dis 2013; 207: 1242-52.
8. Brennan MJ, Thole J. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis 2012; 92:S6-13.
9. Vilaplana C, Montane E, Pinto S, et al. Double-blind, randomized, placebo-controlled Phase I clinical trial of the therapeutical antituberculosis vaccine RUTI. Vaccine 2010; 28:1106-16.
10. Katoch K, Singh P, Adhikari T, et al. Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis. Vaccine 2008; 26:1228-34.
11. Stanford JL, Stanford CA. Immunotherapy of tuberculosis with Mycobacterium vaccae NCTC 11659. Immunobiology 1994; 191:55-63.
12. Turner J, Rhoades ER, Keen M, et al. Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun 2000; 68:1706-9.
13. Guirado E, Gil O, Caceres N, et al. Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis. Clin Vacc Immunol 2008; 15:1229-37.
14. Bertholet S, Ireton GC, Kahn M, et al. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol 2008; 181: 7948-57.